Schroders

Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Cyberhaven is a data security company focused on enhancing the protection of sensitive information from theft and misuse. The company's innovative platform utilizes advanced data tracing technology to analyze billions of events related to each piece of data, allowing for a comprehensive understanding and classification of sensitive information. This capability enables Cyberhaven to protect a wider range of data types in various forms as they move across networks. By assessing internal actions within enterprises, the platform identifies risky behaviors and practices, helping to prevent security breaches. Additionally, it provides full-context data tracing to minimize false positives and negatives, thereby streamlining incident response investigations. Overall, Cyberhaven aims to simplify and strengthen enterprise security, ensuring that organizations can safeguard their critical information effectively.

Luminance is a company that specializes in an AI-powered platform for the generation, negotiation, and analysis of contracts. The platform employs a proprietary legal language model that enhances the processing and comprehension of legal documents, prioritizing accuracy and compliance. By integrating generative and analytical AI, Luminance aids organizations in optimizing contract-related workflows. Its technology leverages various machine learning techniques, including natural language processing and deep neural networks, enabling clients to effectively read and understand a wide range of legal materials. Luminance serves businesses across multiple industries, helping to streamline the review and decision-making processes associated with legal documentation.

Cera Care Limited is a leading provider of digital-first home healthcare services in Europe, specializing in care for elderly individuals. Founded in 2016 and based in London, the company offers a wide range of services including elderly care, palliative care, respite care, post-discharge care, dementia care, and private nursing. Cera Care utilizes advanced technology and data analytics to enhance care delivery, enabling over 10,000 carers and nurses to conduct 60,000 in-person appointments daily. This tech-enabled approach has significantly improved patient outcomes, leading to a reduction in hospitalizations by up to 70%. Cera Care is recognized for its innovative practices, receiving multiple industry awards, including accolades for being the Most Outstanding Home Care Provider. The company was co-founded by Dr. Ben Maruthappu and is supported by an Advisory Board chaired by Sir David Behan, former CEO of the Care Quality Commission. With its commitment to high-quality care and the effective use of technology, Cera Care stands out in the home healthcare sector across multiple regions in the United Kingdom.

Cera Care Limited is a leading provider of digital-first home healthcare services in Europe, specializing in care for elderly individuals. Founded in 2016 and based in London, the company offers a wide range of services including elderly care, palliative care, respite care, post-discharge care, dementia care, and private nursing. Cera Care utilizes advanced technology and data analytics to enhance care delivery, enabling over 10,000 carers and nurses to conduct 60,000 in-person appointments daily. This tech-enabled approach has significantly improved patient outcomes, leading to a reduction in hospitalizations by up to 70%. Cera Care is recognized for its innovative practices, receiving multiple industry awards, including accolades for being the Most Outstanding Home Care Provider. The company was co-founded by Dr. Ben Maruthappu and is supported by an Advisory Board chaired by Sir David Behan, former CEO of the Care Quality Commission. With its commitment to high-quality care and the effective use of technology, Cera Care stands out in the home healthcare sector across multiple regions in the United Kingdom.

Somagenetix is a biotechnology company focused on developing innovative gene therapies for phagocyte-related illnesses, particularly targeting severe inherited immune diseases, immunodeficiency, neurodegeneration, and cancer with brain metastases. The company specializes in discovering and developing stem cells from bone marrow and utilizing lentiviral vectors to deliver therapeutic genes. This approach aims to correct the underlying genetic defects in patients by transplanting gene-corrected cells back into the body, ultimately providing a potential cure for various monogenic disorders. With a commitment to advancing the field of gene therapy, Somagenetix aims to lead in creating first-in-class treatments that address significant medical needs.

Poolside is an artificial intelligence platform that offers foundation concepts and infrastructure. It aims to unlock humanity's potential by pursuing AGI for software creation, with the fundamental belief that the transitional path for humanity to AGI is by building specific capabilities instead of a general-purpose approach. It also helps users utilize the power of software creation and understand future systems.

Enfinity Global, founded in 2005 and headquartered in Bethesda, Maryland, is a prominent player in the renewable energy sector, specializing in the development, financing, construction, and operation of solar energy assets. The company operates globally across Europe, Asia, Africa, and the United States, with a significant presence in countries such as Spain, Italy, Japan, and India. Enfinity is committed to achieving a net-zero carbon footprint and provides comprehensive renewable energy solutions tailored for commercial, municipal, and utility clients. By leveraging its extensive experience in complex renewable energy projects, Enfinity helps organizations transition to sustainable energy sources, thereby facilitating a shift towards a carbon-free economy. The company's expertise and strategic approach enable it to deliver effective energy solutions that meet the growing demand for clean energy worldwide.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Vantage Data Centers specializes in providing data center solutions for major hyper scalers, cloud providers, and large enterprises. Operating across North America, EMEA, and Asia Pacific, the company is recognized for its innovative approach to data center design, emphasizing reliability, efficiency, and sustainability. Vantage's facilities are specifically tailored to meet the demands of high-density computing environments, making them ideal for clients with extensive IT infrastructure requirements. By focusing on wholesale and hyperscale solutions, Vantage enables enterprises to develop customized data storage options that enhance energy efficiency while reducing costs.

Firenze aims to expand financial services by extending investment-backed lending to a wider audience, recognizing its importance in wealth creation and preservation. The founding team aims to democratize Lombard lending, making it accessible to all, while focusing on mass affluent clients.

Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Prodigy Finance Limited operates an online platform that facilitates education loans for international postgraduate and MBA students, enabling them to finance their degrees through a community of lenders. Founded in 2006 and based in London, the platform connects student borrowers with alumni, institutional investors, and qualified private investors, as well as banks. Prodigy Finance specifically targets master's degree students in 18 countries, aiming to make higher education more accessible to individuals who may lack traditional financing options. Additionally, the company offers a mobile app that allows users to manage and access their loan information conveniently.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Cohere is a technology company that specializes in natural language processing (NLP) software, designed to enhance the ability of machines to understand human language. By leveraging advanced large language models, Cohere provides developers and businesses with tools that enable them to create applications capable of interpreting meaning, sentiment, and tone from text. This capability not only improves comprehension but also facilitates the development of more personalized user experiences. The company's focus is on making these sophisticated language models safely accessible, ensuring that organizations can harness the power of NLP to better engage with their users and derive insights from vast amounts of textual data.

Fastned B.V. is a company that constructs and operates fast-charging stations for electric vehicles, primarily in the Netherlands and Germany, with additional operations in the United Kingdom, France, Switzerland, and Belgium. Founded in 2012 and headquartered in Amsterdam, Fastned focuses on providing charging services that utilize renewable energy sources such as solar and wind power. The company aims to establish a European network of 1,000 charging stations located in prime areas, allowing drivers of all-electric vehicles, including popular models like Tesla, Nissan, BMW, and Hyundai, to charge efficiently. In addition to its charging station operations, Fastned also engages in the buying and selling of charging equipment.

Casma Therapeutics, Inc. specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy and lysosomal flux. By focusing on enhancing autophagy, the company aims to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing the progression of various diseases. Its research targets several serious medical conditions, including lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration. Founded in 2017 and based in Cambridge, Massachusetts, Casma Therapeutics is dedicated to creating effective treatment options that meet significant unmet medical needs in the field of drug discovery and development.

Fastned B.V. is a company that constructs and operates fast-charging stations for electric vehicles, primarily in the Netherlands and Germany, with additional operations in the United Kingdom, France, Switzerland, and Belgium. Founded in 2012 and headquartered in Amsterdam, Fastned focuses on providing charging services that utilize renewable energy sources such as solar and wind power. The company aims to establish a European network of 1,000 charging stations located in prime areas, allowing drivers of all-electric vehicles, including popular models like Tesla, Nissan, BMW, and Hyundai, to charge efficiently. In addition to its charging station operations, Fastned also engages in the buying and selling of charging equipment.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Cera Care Limited is a leading provider of digital-first home healthcare services in Europe, specializing in care for elderly individuals. Founded in 2016 and based in London, the company offers a wide range of services including elderly care, palliative care, respite care, post-discharge care, dementia care, and private nursing. Cera Care utilizes advanced technology and data analytics to enhance care delivery, enabling over 10,000 carers and nurses to conduct 60,000 in-person appointments daily. This tech-enabled approach has significantly improved patient outcomes, leading to a reduction in hospitalizations by up to 70%. Cera Care is recognized for its innovative practices, receiving multiple industry awards, including accolades for being the Most Outstanding Home Care Provider. The company was co-founded by Dr. Ben Maruthappu and is supported by an Advisory Board chaired by Sir David Behan, former CEO of the Care Quality Commission. With its commitment to high-quality care and the effective use of technology, Cera Care stands out in the home healthcare sector across multiple regions in the United Kingdom.

Forteus is an asset management firm specializing in blockchain technology and digital assets. The company offers a variety of investment strategies that leverage research, technology, and risk management. Its services include customized portfolios managed by external managers, yield generation, actively managed thematic portfolios, and tokenization. By providing these solutions, Forteus enables investors to engage with trends and investment strategies within the digital asset sector.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Redcliffe Labs is a diagnostics service provider focused on identifying both communicable and non-communicable diseases through advanced radiography and pathology services. The company offers a comprehensive range of standard and specialized tests, utilizing cutting-edge laboratories and in-house technology. Redcliffe Labs aims to enhance accessibility to health tests for all individuals in India by leveraging its trusted radiology network and innovative testing methodologies. Additionally, the company specializes in reproductive health testing, cancer gene diagnosis, and screening for rare diseases, ensuring patients receive thorough support, including regular counseling and clinical data management. Through its extensive testing capabilities, Redcliffe Labs is committed to addressing various aspects of health, pregnancy, and fertility care.

Healthy Workers B.V. is a company based in Amsterdam that focuses on developing B2B solutions aimed at creating healthier work environments for organizations. Founded in 2016, the company offers products such as the WELLBEING-SCAN and an employer dashboard designed to measure and analyze employee well-being. These tools enable employers to identify and address workplace stressors and improve overall employee engagement and productivity. Additionally, Healthy Workers provides consultancy services that encompass various aspects of workplace health, including productivity and stress management. The company operates a SaaS-based platform that leverages data from smart building sensors to enhance workspace efficiency and support sustainability goals. This platform delivers insights on engagement levels and environmental conditions, allowing organizations to make informed decisions to foster healthier and more productive workplaces.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.

Greencoat Capital LLP is a private equity firm based in London, with additional offices in Dublin, Munich, New York, and Chicago. Founded in 2009, the firm specializes in growth capital investments in lower mid-market companies, primarily within the resource efficiency and renewable energy sectors. Greencoat Capital focuses on providing funding for working capital, acquisitions, buyouts, and capital restructuring, while specifically avoiding investments in startup and early-stage companies. Its investment strategies encompass a wide range of renewable energy projects, including wind, solar, hydro, and energy efficiency initiatives. The firm targets investments between €5 million and €30 million in companies with revenues of €10 million to €50 million, typically seeking majority or significant minority stakes and board representation. Greencoat Capital aims for exits within four to seven years and collaborates with other funds for co-investment opportunities. The firm emphasizes a European focus, particularly in Ireland, Great Britain, and Continental Europe, leveraging its relationship with ESB, a leading Irish utility, to enhance its investment capabilities and support portfolio companies.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company is dedicated to discovering and developing transformative therapies for severe liver diseases. Ambys focuses on creating innovative gene, drug, and cell therapies aimed at restoring liver function, halting the progression of liver disease, and addressing the complications associated with liver failure. By leveraging regenerative and restorative medical approaches, Ambys Medicines seeks to improve the lives of individuals affected by chronic liver conditions, providing potential relief through advanced therapeutic options.

euNetworks is a European provider of broadband infrastructure services, focusing on scalable, fiber-based solutions for various industries, including wholesale, content, media, mobile, and finance. The company operates extensive metropolitan networks linked by a high-capacity intercity backbone, enabling it to offer a range of services such as dark fiber, metro wavelength, Ethernet, and colocation. By delivering these services, euNetworks supports the growing bandwidth demands and performance needs of its diverse customer base, positioning itself at the forefront of technological transformation in the telecommunications sector.

Belenergia is an energy company focused on the development, construction, and management of renewable energy facilities, particularly in the areas of solar, wind, and biomass. The company builds and operates large-scale solar power plants and designs biogas and biomethane units that convert organic waste into energy. Through its projects, Belenergia aims to integrate its industrial expertise in renewable technologies while positively impacting local communities.

Cairn Real Estate is an independent investment manager based in Amsterdam. They specialize in managing various assets and investments strategically. With a focus on providing personalized and tailored solutions, Cairn Real Estate works to help clients achieve their financial objectives.

AgroStar, founded in 2013, is a leading AgTech startup in India dedicated to supporting farmers in enhancing their agricultural practices. The company offers an omnichannel platform that provides comprehensive solutions for farmers throughout the crop life cycle, enabling them to increase yields and lower cultivation costs. AgroStar's services include expert advice, tailored content, and access to agricultural inputs such as seeds and nutrients, as well as hardware products. With a strong reliance on data and agronomy expertise, AgroStar effectively reaches millions of farmers across Gujarat, Maharashtra, Rajasthan, Madhya Pradesh, and Uttar Pradesh. Farmers can access these solutions through various channels, including the Agri Advisory Center, the AgroStar Agri Doctor app, and AgroStar retail stores, ensuring convenient support for their agricultural needs.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

RF Eclipse is a Sydney-based provider of commercial mortgage services to the real estate sector. The company specializes in loan origination, loan management, and funds management, catering to various segments including commercial, retail, industrial real estate, and construction. By focusing on these areas, RF Eclipse aims to support clients in securing and managing financing solutions tailored to their specific needs.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

Graphcore Limited is a hardware systems company that specializes in developing intelligent processing units (IPUs) tailored for artificial intelligence and machine learning applications. Founded in 2016 and headquartered in Bristol, United Kingdom, the company offers products such as IPU-Accelerator cards, which enhance server performance for machine learning tasks, and IPU-Appliance systems that improve inference capabilities for various users. Graphcore's innovative IPU architecture allows developers to run existing machine learning models significantly faster, facilitating the deployment of advanced AI solutions across diverse servers and software environments. In addition to its Bristol headquarters, Graphcore has locations in Palo Alto, London, Oslo, and Beijing, expanding its global presence in the AI technology sector.

Sandaire is an international investment company based in London, United Kingdom, specializing in serving wealthy families, private clients, charities, and foundations. Founded in 1996, the firm operates as a multi-family office, providing expert investment counsel and long-term financial support tailored to the unique goals of its clients. Sandaire focuses on creating and maintaining sustainable wealth across generations, ensuring that the financial interests of families and organizations are managed effectively.

Integrity is a life insurance provider in Australia focused on transforming the industry by offering modern and flexible insurance products. The company aims to enhance the customer experience by creating easy-to-understand and accessible products, emphasizing transparency and simplicity. With a strong commitment to service, Integrity blends industry expertise with technology to deliver customized life insurance and wealth management solutions. The company's knowledgeable team prioritizes helping clients, particularly during challenging times, and seeks to establish a new standard of trust and reliability in the life insurance sector.

Pamfleet Group is an independent and privately owned real estate investment advisor with offices in Hong Kong and Singapore. The group was formed in 2000 as a management buy-out of Jardine Fleming’s direct property fund management business. We specialise in identifying underperforming assets and repositioning them to add value. We also provide real estate asset management, investment advisory and asset repositioning services across the region. The management team has been involved in the selection and management of real estate investment properties throughout Asia-Pacific region since 1990, and our characteristics are: - active value-creation (vs. passive appreciation); - reputation for developing innovative transactions; - cycle-tested experience of management team; - full complement of skill-sets within team; and - track record of realised investment returns for investors

BlueOrchard Finance, founded in 2001 and headquartered in Zurich, Switzerland, is a prominent impact investment manager specializing in microfinance. The company focuses on providing debt financing to microfinance institutions across the globe, with local offices in countries such as Cambodia, Georgia, Peru, and Kenya. BlueOrchard has facilitated over USD 2 billion in loans, aiming to enhance financial inclusion for the working poor and improve their living standards. The firm supports various sectors, including energy, education, and sustainable infrastructure, addressing pressing global challenges such as climate change and job creation. BlueOrchard is dedicated to delivering both financial and social returns to investors while promoting a sustainable and inclusive financial system worldwide.

MPM+ Financial PR empowers growth through sustained exposure to enhance investor & shareholder perception and value. MPM+ makes raising capital easier, creates demand for IPOs and Placings, & positions your business leaders as the Key People of Influence in your sector.

Thirdrock Group - Wealth management business provides wealth management services.

Qwil Messenger is a communication software designed to facilitate secure and compliant B2B messaging. The platform features a single chat application that enables businesses to create a GDPR-compliant communication channel for interactions with staff, clients, and partners. It allows users to initiate virtual meetings with a single click and store files securely in one location. Qwil Messenger supports integration with 200 endpoints, enabling automation as business needs evolve. The application is designed for multiple firms and their clients, providing a branded space that is fully controlled and coordinated by each organization. Its proprietary technology allows for rapid deployment across various jurisdictions, ensuring scalability and compliance in communication.

WeInvest is a Singapore-based online platform established in 2013 that facilitates individual investors in exploring various investment opportunities, including real estate, mutual funds, and deposits. The platform provides users with investment ideas, helps them identify suitable products, and enables tracking of their investment portfolios. Additionally, it offers connections to prospective brokers and advisors. WeInvest operates as a digital wealth management service, aiming to make investing more accessible and transparent. It provides aggregation services and features such as robo-advisory and goal-based investing, empowering banks, wealth managers, insurance companies, and independent financial advisors to better engage with their clients, plan investments, and analyze portfolio performance.

Algonquin SA, founded in 1998 and based in Brussels, Belgium, specializes in the investment, ownership, operation, and franchising of hotels across Europe. The company manages a portfolio of 43 hotel assets, offering over 7,500 rooms with an estimated value of €1.8 billion. Approximately half of these hotels operate under Algonquin's own brands or well-known international franchises, while the remainder is managed through agreements with major international operators. Algonquin distinguishes itself by actively engaging in hotel operations, providing expertise in both daily management tasks and real estate matters. This dual role allows Algonquin to optimize operational efficiency and enhance the value of its properties, making it an attractive partner for institutional investors, family offices, and private equity firms seeking to collaborate in dedicated investment vehicles.

Adveq, founded in 1997, is a prominent asset manager specializing in investments in private equity and real asset funds on a global scale. The firm offers tailored investment solutions that enable clients to access specific private market segments worldwide. With a strong track record, Adveq has invested in over 400 funds, consistently delivering returns across various economic conditions. Its clientele consists primarily of institutional investors, including pension funds, insurance companies, family offices, and other financial institutions from Europe, North America, and the Asia-Pacific region. Adveq has cultivated long-lasting relationships with many of its investors, establishing itself as a trusted partner in private market investing. The company operates offices in Zurich, Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, alongside an agent relationship in Sydney.

Nutmeg is a London-based company founded in 2011 that specializes in digital wealth management, focusing on investments, ISAs, and pensions. The company offers an online investment management service that aims to simplify the investment process for individuals by providing easy access to sophisticated global investment portfolios. Nutmeg's platform is designed to maintain low costs and charges while enhancing returns, enabling clients to make informed investment decisions and work towards their financial goals. As the first wealth manager in the UK with a six-year performance track record, Nutmeg is dedicated to changing the way people manage their money through an intelligent and straightforward approach.

Benchmark Capital, established in 2015, specializes in offering comprehensive digital wealth management solutions aimed at enhancing the growth and success of financial advisory firms. By integrating advanced technology, investment solutions, and support services, Benchmark Capital empowers over 120 leading national and regional firms to deliver differentiated client propositions. The company focuses on unifying the fragmented financial services industry, providing its clients with the tools and insights necessary to gain a competitive edge.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

Nutmeg is a London-based company founded in 2011 that specializes in digital wealth management, focusing on investments, ISAs, and pensions. The company offers an online investment management service that aims to simplify the investment process for individuals by providing easy access to sophisticated global investment portfolios. Nutmeg's platform is designed to maintain low costs and charges while enhancing returns, enabling clients to make informed investment decisions and work towards their financial goals. As the first wealth manager in the UK with a six-year performance track record, Nutmeg is dedicated to changing the way people manage their money through an intelligent and straightforward approach.

Cazenove Capital Management is a London-based wealth management firm that has been operating since 1823. The firm specializes in providing personalized wealth management services to a diverse clientele, including private clients, family offices, trusts, companies, and pension plans. Cazenove Capital focuses on preserving and growing its clients' wealth, emphasizing a tailored approach to financial planning and investment management. The firm collaborates closely with financial advisers, assisting them in offering discretionary fund management services. Cazenove Capital is dedicated to understanding and addressing what matters most to its clients, ensuring a commitment to their financial well-being.

STW Fixed Income Management Ltd. is an employee-owned investment manager based in Santa Barbara, California, managing approximately $11 billion in assets. Founded in 1977, the firm specializes in fixed income investment management for a diverse clientele, including pensions, foundations, endowments, family offices, insurance companies, and various trusts. STW focuses on creating separate client-oriented portfolios, primarily investing in the public fixed income markets of the United States. The firm emphasizes sectors such as technology, particularly in technical infrastructure and software development, and exclusively invests in investment-grade fixed income value securities. Utilizing both fundamental and quantitative analysis, STW aims to optimize portfolio performance while adhering to its clients' specific investment objectives.

GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

Orthomimetics was founded in 2005 as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). Its products are based on a leading collagen biomaterials platform for the production of scaffolds for cartilage, meniscus, ligament and tendon repair. Orthomimetics’ flagship product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval) and is close to entering the European market. Small osteochondral defects represent an important medical need that is currently not covered by TiGenix’ products. Chondromimetic™ forms an excellent fit with TiGenix’ lead product, ChondroCelect®, since both products target the same customer base in complementary indications.

Newfinance Capital is a London-based funds of hedge funds manager.

Square Enix is a prominent developer, publisher, and distributor of interactive entertainment, known for its influential digital content. Founded in 1989 and headquartered in El Segundo, California, the company has established a strong global presence with development studios in North America, Europe, and Japan. Square Enix is recognized for its iconic franchises, including Final Fantasy, Dragon Quest, and Tomb Raider, alongside other titles such as Deus Ex and Just Cause. The company offers a diverse array of products, encompassing online games, mobile entertainment, music, and multimedia content. Additionally, Square Enix provides the PlayOnline platform, facilitating cross-platform online community interactions and multiplayer experiences across various operating systems. Its commitment to delivering high-quality entertainment content has made Square Enix a key player in the global gaming industry.

CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, that specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. Founded in 2000, the company focuses on creating a pipeline of kinase inhibitors that act on inflammatory mediators, offering oral therapeutic options for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

iCollector, founded in 1997 and based in Port Coquitlam, Canada, operates a comprehensive online auction platform that connects auctioneers with buyers worldwide. The platform features a diverse range of auction items, including coins, vintage collectibles, gaming memorabilia, collectible firearms, movie props, original set costumes, and unique jewelry. With over 1,000 auction house clients, iCollector offers pay-per-use access to its platform, allowing clients to list items in a catalog format aligned with their physical auctions. Bidders can register for free, place and modify bids, and participate in live auctions in real time. iCollector has conducted over 10,000 auctions, utilizing a robust database to provide valuable insights and support to both bidders and auction houses. The company also offers marketing assistance, auction house support, and integration of payment and shipping functions to streamline operations. iCollector shares resources with its sister platform, LiveAuctionWorld, and is part of a brand group that includes LiveAuctionGroup, which specializes in custom software solutions for the auction industry.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.